Literature DB >> 1562761

Structure-function interactions in the therapeutic response of diabetic neuropathy.

A A Sima1.   

Abstract

Conventional electrophysiologic measurements such as nerve conduction velocity, compound action potential, and neuropathic symptom scores have been used to assess the severity of diabetic neuropathy and have been the major efficacy end points following pharmacologic intervention trials. Unfortunately, these measurements are not particularly sensitive and their reproducibility is, at best, good. Detailed morphometric analysis of sural nerve biopsies has evolved as a sensitive and highly reproducible method for assessing the severity and progression of diabetic peripheral neuropathy. In this study we demonstrate highly significant correlations between morphometric parameters of diabetic sural nerves and electrophysiologic and sensory score measurements of the same sural nerve. These data suggest that detailed morphometric examination is a more sensitive and reproducible method for assessing the severity of diabetic neuropathy, and that quantitative morphometric parameters provide sensitive indicators of electrophysiologic and clinically meaningful nerve damage. Morphometric analysis of sural nerve biopsies therefore constitutes a rational basis for sensitive efficacy end points in the design of future therapeutic clinical trials.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1562761     DOI: 10.1016/1056-8727(92)90051-l

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  3 in total

1.  Advanced Diabetic Neuropathy: A Point of no Return?

Authors:  Petr Boucek
Journal:  Rev Diabet Stud       Date:  2006-11-10

2.  Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT.

Authors:  S E Siegelaar; E S Kilpatrick; A S Rigby; S L Atkin; J B L Hoekstra; J H Devries
Journal:  Diabetologia       Date:  2009-08-12       Impact factor: 10.122

3.  Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study.

Authors:  Jaime Hernández-Ojeda; Luis Miguel Román-Pintos; Adolfo Daniel Rodríguez-Carrízalez; Rogelio Troyo-Sanromán; Ernesto Germán Cardona-Muñoz; María Del Pilar Alatorre-Carranza; Alejandra Guillermina Miranda-Díaz
Journal:  Diabetes Metab Syndr Obes       Date:  2014-09-04       Impact factor: 3.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.